Biologics processes continue to evolve after approval. This guide explains how ICH Q12 uses Established Conditions, PACMPs, PLCM documents, and the PQS to make post-approval CMC changes more predictable and risk-based.

A 2026 Science study uses CRISPR TAPIR to increase rRNA transcription and asks whether translation capacity itself can shape stem cell fate, linking ribosome biology with regeneration, ribosomopathies, and cancer.

Biologics quality cannot rely on release testing alone. This guide explains how to build an integrated strategy across materials, manufacturing, analytics, specifications, and continued monitoring.

A practical, end-to-end guide to mRNA-LNP CMC—from templates, IVT mRNA, lipid raw materials, and scale-up to potency, stability, comparability, and current global regulatory expectations.

The bottleneck in In Vivo CAR T may be delivery rather than the CAR itself. This article examines ERTLNP, T-cell activation, mTOR signaling, CMC implications, and the emerging 2026 clinical landscape.

Passing release specifications does not establish comparability. Learn how ICH Q5E integrates risk assessment, analytical characterization, stability, process data, and regulatory strategy.

A biologics specification is not simply a table of tests and limits. This guide explains how ICH Q6B connects product characterization, critical quality attributes, release testing, acceptance criteria, CTD Module 3, and the evolving direction of Q6(R1).

Four ISSCR 2026 keynotes point to one conclusion: gene delivery is the real bottleneck in cell and gene therapy. What it means for CMC, CDMOs, and capital.

Executive Summary If you only have three minutes to read this article, here are five key takeaways: Aging is increasingly viewed as a biological process that can potentially be modified, rather than an inevitable consequence of time. The discovery of the Yamanaka Factors revolutionized modern biology by demonstrating that cell identity is reversible, leading to the development of induced pluripotent stem cells (iPSCs). Today, the most exciting direction in aging research is P

Executive Summary If you only have three minutes to read this article, I hope you'll remember these six things first. The real challenge of Gene Therapy is not just finding the therapeutic gene, but how to safely and effectively deliver the gene into the right cells. AAV (Adeno-associated virus) is one of the most mature in vivo gene delivery platforms currently available. Researchers remove most of the virus's genes, retaining only the structures needed for delivery, and the

學士、碩士、博士不是越高越好，而是要看你想用學位換到什麼職涯選擇權。這篇用 2026 年職場現實、研究訓練、biotech 與跨領域案例，幫你判斷該直接工作、念碩士，還是投入博士。

Figure 1. Evolution from autologous to off-the-shelf cell therapy. Comparison of autologous and allogeneic cell therapy manufacturing workflows. Unlike patient-specific manufacturing, iPSC-derived allogeneic therapies leverage Master Cell Banks (MCBs), standardized manufacturing processes, and large-scale production to enable scalable, off-the-shelf regenerative medicine. Executive Summary Key Takeaways Induced pluripotent stem cells (iPSCs) have evolved from a stem cell tech

Figure 1. The Journey of Induced Pluripotent Stem Cells (iPSCs): From Somatic Cell Reprogramming to Regenerative Medicine. Adult somatic cells can be reprogrammed into induced pluripotent stem cells (iPSCs), expanded and banked, differentiated into specialized cell types, and applied in disease modeling, drug discovery, regenerative medicine, and cell therapy. This workflow highlights how iPSCs serve as a foundational platform technology connecting basic research with transla

Executive Summary Pfizer has introduced a new platform called USTAT (Unified Sequential Template Amplification and Transcription). The platform uses Rolling Circle Amplification (RCA) to establish an mRNA manufacturing process that does not rely on traditional plasmid DNA. The time from DNA template generation to mRNA production can potentially be reduced to approximately two days. RNA quality approaches that of conventional plasmid DNA-based manufacturing, although challenge

Introduction: For the First Time, Treatment Is About More Than Controlling Blood Sugar For more than a century, the treatment of Type 1 Diabetes (T1D) has been relatively straightforward. If the body cannot produce insulin, we replace insulin. This approach has saved millions of lives since the discovery of insulin in 1921. However, if we look deeper, one important fact becomes apparent: We have never truly addressed the underlying disease. The problem is not simply a lack of

Introduction: Many People Think mRNA Has Already Succeeded — But It’s Just Getting Started Ask most people what mRNA is, and you’ll probably hear answers like: COVID-19 vaccines Moderna Pfizer The breakthrough technology of the pandemic And they wouldn’t be wrong. COVID-19 vaccines represent one of the most successful commercial applications of mRNA technology in history. However, if you ask scientists working in RNA therapeutics, gene therapy, or drug delivery, you may hear

Introduction: The Next Bottleneck in mRNA Therapeutics May Not Be RNA—It May Be the LNP Since the successful launch of COVID-19 mRNA vaccines, mRNA technology has rapidly expanded beyond infectious diseases into areas such as cancer immunotherapy, gene editing, protein replacement therapy, and regenerative medicine. Many scientists believe the next decade will be the golden age of RNA therapeutics. However, anyone who has worked in mRNA drug development quickly realizes a fun

Introduction How Amino Acids Enhance LNP mRNA Delivery: A New Direction for mRNA Therapeutics Over the past few years, lipid nanoparticles (LNPs) have become the cornerstone of modern mRNA therapeutics. From COVID-19 mRNA vaccines to cancer immunotherapy, rare disease treatment, and gene editing, LNPs are now one of the most important delivery platforms for nucleic acid medicines. But anyone who has worked in drug delivery knows a frustrating reality: An LNP system that perfo

Introduction: Treatment Is No Longer Just About Controlling Blood Glucose For decades, the treatment of Type 1 Diabetes (T1D) has been relatively straightforward. If the body cannot produce insulin, we replace it. This approach works. It allows patients to manage the disease and maintain quality of life. But if you look one layer deeper, a fundamental limitation becomes clear: We have never truly changed the disease itself. The problem is not just a lack of insulin.It is that

Introduction: This Is Not a Sudden Disease Most people think of Type 1 Diabetes (T1D) as something that suddenly appears —one day you’re diagnosed, and from that point on, you depend on insulin. But from a biological perspective, T1D is not an abrupt event.It is a long, gradual process that can unfold over years, even decades. At the center of this process is the progressive breakdown of the Type 1 Diabetes autoimmune mechanism. The real question is not about blood glucose.It